Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 48Multiple Myeloma 39Lymphoma, Large B-Cell, Diffuse 38Burkitt Lymphoma 34Lymphoma 31Leukemia, Myeloid, Acute 31Lymphoma, Non-Hodgkin 29Recurrence 27Breast Neoplasms 27Neoplasms 23Lymphoma, B-Cell 23Myelodysplastic Syndromes 22Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Follicular 20Hodgkin Disease 18Triple Negative Breast Neoplasms 17Melanoma 17Leukemia 17Ovarian Neoplasms 16Hematologic Neoplasms 15Neuroblastoma 14Lymphoma, Mantle-Cell 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 12Pancreatic Neoplasms 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 12Leukemia, Biphenotypic, Acute 11Neoplasm Metastasis 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelomonocytic, Chronic 10Sarcoma 9

Interventions

Vincristine 1Radiotherapy 1Irinotecan 1Ifosfamide 1Filgrastim 1Etoposide 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant mesenchymal tumor × Cyclophosphamide × 90 days × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡